Thermo Fisher Scientific Inc. (New York Stock Exchange:TMO)
| Market Cap | 225.09B+27.1% |
| Revenue (ttm) | 46.34B+7.2% |
| Net Income | 6.98B+6.0% |
| EPS | 18.59+7.6% |
| Shares Out | 371.62M |
| PE Ratio | 32.53 |
| Forward PE | 22.11 |
| Dividend | $1.80(0.30%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 1,919,360 |
| Open | 601.93 |
| Previous Close | 603.02 |
| Day's Range | 597.31 - 609.51 |
| 52-Week Range | 435.27 - 647.00 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 623.36(+2.92%) |
| Earnings Date | Oct 28, 2026 |
About TMO
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TMO stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of TMO by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro KhannaHouse / D | Purchase$1.00K – $15.00K | Aug 7, 2026 |
| Kelly MorrisonHouse / D | Sale$15.00K – $50.00K | Aug 18, 2025 |
| Kelly MorrisonHouse / D | Sale$1.00K – $15.00K | Aug 18, 2025 |
| Rick W. AllenHouse / R | Sale$15.00K – $50.00K | May 15, 2025 |
| Thomas H. KeanHouse / R | Purchase$1.00K – $15.00K | May 5, 2025 |
| Thomas KeanHouse / R | Purchase$1.00K – $15.00K | May 4, 2025 |
| Rick W. AllenHouse / R | Sale$15.00K – $50.00K | Apr 10, 2025 |
| Michael RulliHouse / R | Sale$1.00K – $15.00K | Dec 12, 2024 |
Recently reported changes in TMO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TMO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TMO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TMO Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New TMO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TMO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TMO
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.80B |
| VOOVanguard S&P 500 ETF | $5.60B |
| IVViShares Core S&P 500 ETF | $3.01B |
| SPYState Street SPDR S&P 500 ETF | $2.75B |
| VTVVanguard Morningstar Value ETF | $2.03B |
| XLVState Street Health Care Select Sector SPDR ETF | $1.65B |
Estimated from each fund’s disclosed top holdings × AUM
TMO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TMO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score